O	0	3	The
O	4	7	use
O	8	10	of
B-intervention	11	17	Ginkgo
I-intervention	18	24	biloba
O	25	28	for
O	29	32	the
O	33	43	prevention
O	44	46	of
B-condition	47	59	chemotherapy
I-condition	59	60	-
I-condition	60	67	related
I-condition	68	77	cognitive
I-condition	78	89	dysfunction
O	90	92	in
O	93	98	women
O	99	108	receiving
O	109	117	adjuvant
O	118	127	treatment
O	128	131	for
O	132	138	breast
O	139	145	cancer
O	145	146	,
O	147	152	N00C9
O	152	153	.

O	154	162	Patients
O	163	173	undergoing
O	174	183	treatment
O	184	187	for
O	188	194	cancer
O	195	200	often
O	201	207	report
O	208	216	problems
O	217	221	with
O	222	227	their
O	228	237	cognitive
O	238	246	function
O	246	247	,
O	248	253	which
O	254	256	is
O	257	259	an
O	260	269	essential
O	270	279	component
O	280	282	of
O	283	289	health
O	289	290	-
O	290	297	related
O	298	305	quality
O	306	308	of
O	309	313	life
O	313	314	.

O	315	323	Pursuant
O	324	326	to
O	327	331	this
O	331	332	,
O	333	334	a
O	335	338	two
O	338	339	-
O	339	342	arm
O	343	353	randomized
O	353	354	,
O	355	362	placebo
O	362	363	-
O	363	373	controlled
O	373	374	,
O	375	381	double
O	381	382	-
O	382	387	blind
O	387	388	,
O	389	394	phase
O	395	398	III
O	399	407	clinical
O	408	413	trial
O	414	417	was
O	418	427	conducted
O	428	430	to
O	431	439	evaluate
O	440	446	Ginkgo
O	447	453	biloba
O	454	455	(
O	455	458	EGB
O	459	462	761
O	462	463	)
O	464	467	for
O	468	471	the
O	472	482	prevention
O	483	485	of
O	486	498	chemotherapy
O	498	499	-
O	499	506	related
O	507	516	cognitive
O	517	528	dysfunction
O	529	531	in
O	532	540	patients
O	541	545	with
O	546	552	breast
O	553	559	cancer
O	559	560	.

B-eligibility	561	571	Previously
I-eligibility	572	584	chemotherapy
I-eligibility	585	587	na
I-eligibility	587	588	Ã¯
I-eligibility	588	590	ve
I-eligibility	591	596	women
I-eligibility	597	602	about
I-eligibility	603	605	to
I-eligibility	606	613	receive
I-eligibility	614	622	adjuvant
I-eligibility	623	635	chemotherapy
I-eligibility	636	639	for
I-eligibility	640	646	breast
I-eligibility	647	653	cancer
O	654	658	were
O	659	669	randomized
O	670	672	to
O	673	680	receive
O	681	683	60
O	684	686	mg
O	687	689	of
O	690	693	EGB
O	694	697	761
O	698	700	or
O	701	702	a
O	703	711	matching
B-control	712	719	placebo
O	720	725	twice
O	726	731	daily
O	731	732	.

O	733	736	The
O	737	742	study
O	743	748	agent
O	749	752	was
O	753	755	to
O	756	761	begin
O	762	768	before
O	769	774	their
O	775	781	second
O	782	787	cycle
O	788	790	of
O	791	803	chemotherapy
O	804	807	and
O	808	810	to
O	811	813	be
O	814	819	taken
O	820	830	throughout
O	831	843	chemotherapy
O	844	847	and
O	848	849	1
O	850	855	month
O	856	862	beyond
O	863	873	completion
O	873	874	.

O	875	878	The
O	879	886	primary
O	887	894	measure
O	895	898	for
O	899	908	cognitive
O	909	917	function
O	918	921	was
O	922	925	the
B-outcome-Measure	926	930	High
I-outcome-Measure	931	942	Sensitivity
I-outcome-Measure	943	952	Cognitive
I-outcome-Measure	953	959	Screen
I-outcome-Measure	960	961	(
I-outcome-Measure	961	965	HSCS
I-outcome-Measure	965	966	)
O	966	967	,
O	968	972	with
O	973	974	a
O	975	984	secondary
O	985	992	measure
O	993	998	being
O	999	1002	the
B-outcome-Measure	1003	1008	Trail
I-outcome-Measure	1009	1015	Making
I-outcome-Measure	1016	1021	Tests
I-outcome-Measure	1022	1023	(
I-outcome-Measure	1023	1026	TMT
I-outcome-Measure	1026	1027	)
I-outcome-Measure	1028	1029	A
I-outcome-Measure	1030	1033	and
I-outcome-Measure	1034	1035	B
O	1035	1036	.

O	1037	1047	Subjective
O	1048	1058	assessment
O	1059	1061	of
O	1062	1071	cognitive
O	1072	1080	function
O	1081	1084	was
O	1085	1094	evaluated
O	1095	1097	by
O	1098	1101	the
O	1102	1111	cognitive
O	1112	1120	subscale
O	1121	1123	of
O	1124	1127	the
O	1128	1137	Perceived
O	1138	1144	Health
O	1145	1150	Scale
O	1151	1152	(
O	1152	1155	PHS
O	1155	1156	)
O	1157	1160	and
O	1161	1164	the
O	1165	1172	Profile
O	1173	1175	of
O	1176	1180	Mood
O	1181	1187	States
O	1188	1189	(
O	1189	1193	POMS
O	1193	1194	)
O	1194	1195	.

O	1196	1200	Data
O	1201	1205	were
O	1206	1215	collected
O	1216	1218	at
O	1219	1227	baseline
O	1228	1231	and
O	1232	1234	at
O	1235	1244	intervals
O	1245	1255	throughout
O	1256	1259	and
O	1260	1265	after
O	1266	1278	chemotherapy
O	1278	1279	,
O	1280	1282	up
O	1283	1285	to
O	1286	1288	24
O	1289	1295	months
O	1296	1301	after
O	1302	1312	completion
O	1313	1315	of
O	1316	1324	adjuvant
O	1325	1334	treatment
O	1334	1335	.

O	1336	1339	The
O	1340	1347	primary
O	1348	1359	statistical
O	1360	1368	analysis
O	1369	1377	included
O	1378	1388	normalized
O	1389	1393	area
O	1394	1399	under
O	1400	1403	the
O	1404	1409	curve
O	1410	1411	(
O	1411	1414	AUC
O	1414	1415	)
O	1416	1427	comparisons
O	1428	1430	of
O	1431	1434	the
O	1435	1439	HSCS
O	1439	1440	,
O	1441	1448	between
O	1449	1452	the
O	1453	1457	arms
O	1457	1458	.

O	1459	1468	Secondary
O	1469	1477	analyses
O	1478	1486	included
O	1487	1497	evaluation
O	1498	1500	of
O	1501	1504	the
O	1505	1510	other
O	1511	1519	measures
O	1520	1522	of
O	1523	1532	cognition
O	1533	1535	as
O	1536	1540	well
O	1541	1543	as
O	1544	1557	correlational
O	1558	1566	analyses
O	1567	1574	between
O	1575	1579	self
O	1579	1580	-
O	1580	1586	report
O	1587	1590	and
O	1591	1600	cognitive
O	1601	1608	testing
O	1608	1609	.

B-total-participants	1610	1613	One
I-total-participants	1614	1621	hundred
I-total-participants	1622	1625	and
I-total-participants	1626	1631	sixty
I-total-participants	1631	1632	-
I-total-participants	1632	1635	six
O	1636	1641	women
O	1642	1650	provided
O	1651	1660	evaluable
O	1661	1665	data
O	1665	1666	.

O	1667	1672	There
O	1673	1677	were
O	1678	1680	no
O	1681	1692	significant
B-outcome	1693	1704	differences
I-outcome	1705	1707	in
I-outcome	1708	1711	AUC
O	1712	1714	up
O	1715	1717	to
O	1718	1720	12
O	1721	1727	months
O	1728	1730	on
O	1731	1734	the
O	1735	1739	HSCS
O	1740	1747	between
O	1748	1752	arms
O	1753	1755	at
O	1756	1759	the
O	1760	1763	end
O	1764	1766	of
O	1767	1779	chemotherapy
O	1780	1782	or
O	1783	1785	at
O	1786	1789	any
O	1790	1795	other
O	1796	1800	time
O	1801	1806	point
O	1807	1812	after
O	1813	1821	adjuvant
O	1822	1831	treatment
O	1831	1832	.

O	1833	1838	There
O	1839	1843	were
O	1844	1848	also
O	1849	1851	no
O	1852	1863	significant
B-outcome	1864	1875	differences
I-outcome	1876	1878	in
I-outcome	1879	1882	TMT
I-outcome	1883	1884	A
I-outcome	1885	1887	or
I-outcome	1888	1889	B
O	1890	1892	at
O	1893	1896	any
O	1897	1901	data
O	1902	1907	point
O	1907	1908	.

B-outcome	1909	1918	Perceived
I-outcome	1919	1928	cognitive
I-outcome	1929	1938	functions
O	1938	1939	,
O	1940	1942	as
O	1943	1951	measured
O	1952	1954	by
O	1955	1958	the
O	1959	1962	PHS
O	1963	1966	and
O	1967	1976	confusion
O	1976	1977	/
O	1977	1989	bewilderment
O	1990	1998	subscale
O	1999	2001	of
O	2002	2005	the
O	2006	2010	POMS
O	2010	2011	,
O	2012	2016	were
O	2017	2020	not
O	2021	2030	different
O	2031	2038	between
O	2039	2043	arms
O	2044	2046	at
O	2047	2050	the
O	2051	2054	end
O	2055	2057	of
O	2058	2070	chemotherapy
O	2070	2071	.

O	2072	2077	There
O	2078	2081	was
O	2082	2086	also
O	2087	2093	little
O	2094	2105	correlation
O	2106	2113	between
B-outcome	2114	2118	self
I-outcome	2118	2119	-
I-outcome	2119	2127	reported
I-outcome	2128	2137	cognition
I-outcome	2138	2141	and
I-outcome	2142	2151	cognitive
I-outcome	2152	2159	testing
O	2159	2160	.

O	2161	2163	No
O	2164	2175	differences
O	2176	2180	were
O	2181	2189	observed
O	2190	2192	in
B-outcome	2193	2203	toxicities
O	2204	2207	per
O	2208	2214	Common
O	2215	2226	Terminology
O	2227	2235	Criteria
O	2236	2239	for
O	2240	2247	Adverse
O	2248	2254	Events
O	2255	2256	(
O	2256	2261	CTCAE
O	2261	2262	)
O	2263	2273	assessment
O	2274	2281	between
O	2282	2288	Ginkgo
O	2289	2295	biloba
O	2296	2299	and
O	2300	2307	placebo
O	2308	2318	throughout
O	2319	2322	the
O	2323	2328	study
O	2328	2329	;
O	2330	2337	however
O	2337	2338	,
O	2339	2344	after
O	2345	2357	chemotherapy
O	2357	2358	,
O	2359	2362	the
O	2363	2370	placebo
O	2371	2376	group
O	2377	2385	reported
O	2386	2391	worse
O	2392	2398	nausea
O	2399	2400	(
O	2400	2401	p
O	2402	2403	=
O	2404	2405	.
O	2405	2407	05
O	2407	2408	)
O	2408	2409	.

O	2410	2414	This
O	2415	2420	study
O	2421	2424	did
O	2425	2428	not
O	2429	2436	provide
O	2437	2440	any
O	2441	2448	support
O	2449	2452	for
O	2453	2456	the
O	2457	2463	notion
O	2464	2468	that
O	2469	2475	Ginkgo
O	2476	2482	biloba
O	2482	2483	,
O	2484	2486	at
O	2487	2488	a
O	2489	2493	dose
O	2494	2496	of
O	2497	2499	60
O	2500	2502	mg
O	2503	2508	twice
O	2509	2510	a
O	2511	2514	day
O	2514	2515	,
O	2516	2519	can
O	2520	2524	help
O	2525	2532	prevent
O	2533	2542	cognitive
O	2543	2550	changes
O	2551	2555	from
O	2556	2568	chemotherapy
O	2568	2569	.

O	2570	2575	These
O	2576	2584	analyses
O	2585	2587	do
O	2588	2595	provide
O	2596	2600	data
O	2601	2603	to
O	2604	2611	further
O	2612	2619	support
O	2620	2623	the
O	2624	2627	low
O	2628	2640	associations
O	2641	2648	between
O	2649	2657	patients
O	2657	2658	'
O	2659	2663	self
O	2663	2664	-
O	2664	2670	report
O	2671	2673	of
O	2674	2683	cognition
O	2684	2687	and
O	2688	2697	cognitive
O	2698	2709	performance
O	2709	2710	,
O	2711	2716	based
O	2717	2719	on
O	2720	2724	more
O	2725	2731	formal
O	2732	2739	testing
O	2739	2740	.
